Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Magali Taiel, MD, of GenSight Biologics, Paris, France, discusses the long-term follow-up results of RESCUE and REVERSE, two Phase III clinical trials evaluating LUMEVOQ gene therapy in patients with Leber hereditary optic neuropathy. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.